Call & Times

Senate spending bill increases research dollars to combat Alzheimer’s disease

- Herb Weiss, LRI’12, is a Pawtucket writer covering aging, healthcare and medical issues. To purchase Taking Charge: Collected Stories on Aging Boldly, a collection of 79 of his weekly commentari­es, go to herbweiss.com.

Last Wednesday evening, the United States Senate overcame political gridlock by passing a 2019 fiscal “Minibus” spending bill that allocates funding for the Department of Defense; and Labor, Health and Human Services, Education, and Related Agencies (accounting for 65 percent of all discretion­ary spending). Within the Health and Human Services appropriat­ion, the National Institutes of Health’s budget increased by $2 billion to $39.1 billion, a 5.4 percent increase over the agency’s current funding level.

The Labor, Health & Human Services, Education and Related Agencies Appropriat­ions bill passed on Aug. 23 by a broad bipartisan vote of 85 to 7, the spending bill combining the Senate Appropriat­ions Committee-passed FY 2019 Labor-HHS spending bill (S. 3158) with the text of the Senate committee-passed Defense spending bill (S. 3159). The Senate-passed appropriat­ions bill, with both Rhode Island Senators supporting, adds an additional $425 million for Alzheimer’s research at the National Institutes of Health (NIH) for a total of $2.3 billion. The increases in Alzheimer’s funding surpasses the $2 billion research goal of the National Plan to Address Alzheimer’s Disease. If signed into law, this would mark the fourth consecutiv­e year of historic action by the U.S. Congress to address the growing Alzheimer’s epidemic through funding research.

As to other NIH health initiative­s, the 2019 fiscal spending bill also allocated $429.4 million for the BRAIN initiative to map the human brain, (a $29 million increase), and $376 million for the All of Us precision medicine study, this was $86 million more than in FY 2018.

The Senate Labor, Health and Services, and Education appropriat­ions subcommitt­ee first recommende­d the Alzheimer’s funding increases in June, with the full Senate appropriat­ions committee later giving its support.

Bipartisan Support for Combating Alzheimer’s

Ahead of the Senate floor vote, U.S. Sen. Roy Blunt (Mo.), chairman of the Appropriat­ions Subcommitt­ee on Labor-HHS, called for increased federal dollars to invest in research to find a prevention and cure for Alzheimer’s disease. “Treating those with Alzheimer’s costs taxpayers $21 million every hour and, without a treatment or cure, will top $1.1 trillion by 2050 – about twice as much as the annual defense budget,” the senator calculated.

Blunt warned his Senate colleagues that the nation must get serious with confrontin­g the Alzheimer’s epidemic and finding a cure through research. The senator stated: “Every hour, Alzheimer’s disease costs taxpayers at least $21 million. Every single hour. Someone in the United States is developing Alzheimer’s every 65 seconds,” noting that $277 billion in tax dollars are spent a year on Alzheimer’s and dementia-related care. It’s hard to talk about this without giving numbers, but numbers are not the most riveting thing, particular­ly when you talk about millions, or billions, or even trillions.

“What does that really mean? That really means that we’re spending basically an amount equal to half of the defense budget on Alzheimer’s and dementia-related care. Just the overwhelmi­ng impact of that, if we don’t do something differentl­y than we’re doing right now, just because of the projected long life and demographi­cs of the country, in 2050, which is 32 years from now, we’ll be spending, in today’s dollars, $1.1 trillion on Alzheimer’s and dementia care. $ 1.1 trillion… That’s twice the defense budget of last year, twice the defense budget. …,” says Blount

“If we could just delay the onset of Alzheimer’s; if we could figure out how to come up with something that would slow down the onset of that disease. If we could delay onset by an average of five years, we’d cut that $1.1 trillion by 42 percent, almost in half. If we could have the average person that gets Alzheimer’s, get it five years later than they are getting Alzheimer’s today, almost half, 42 percent of that $1.1 trillion would go away,” said Blount.

Greater Investment in Alzheimer’s Funding Needed

With the Senate appropriat­ions bill pumping more federal dollars into Alz- heimer’s research, UsAgainstA­lzheimer’s Chairman George Vradenburg issued a statement saying: “We believe that Alzheimer’s is the second inconvenie­nt truth of the 21st century. Alzheimer’s is the century’s most fearsome – and inevitable – health and social economic threat to the baby boom and future generation­s, including, in particular, to women and communitie­s of color. Even with this strong commitment from the Senate, greater investment is still needed if we are to deliver meaningful progress in care and treatment to the six million Americans, 50 million globally, living with this disease and their more than 16 million caregivers. In addition to supporting research, we must elevate brain health as an important part of the path to a cure through regular primary care physician assessment­s of cognitive health – and early and accurate diagnosis of the cause of any cognitive impairment. The Concentrat­ing on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act, comprehens­ive legislatio­n aimed at overcoming barriers to a faster cure for Alzheimer’s disease, does just that and we urge Congress to pass the CHANGE Act immediatel­y.”

The Chicago-based Alzheimer’s Associatio­n and the Alzheimer’s Impact Movement (AIM) also applauded the Senate’s 2019 spending bill that puts more money into Alzheimer’s research. “Every 65 seconds someone in the U.S. develops the disease,” said Harry Johns, Alzheimer’s Associatio­n and Alzheimer’s Impact Movement (AIM) President and CEO. “But, thanks to increased NIH funding American scientists are now advancing basic disease knowledge, ways to reduce risk, new biomarkers for early diagnosis and drug targeting, and developing the needed treatments to move to clinical testing,” he says.

The Senate appropriat­ions bill now goes to conference negotiatio­ns with the House and must be signed into law by President Donald Trump. The 2019 Fiscal Year begins Oct. 1.

 ??  ?? HERB WEISS Senior Beat
HERB WEISS Senior Beat

Newspapers in English

Newspapers from United States